Sun Yiyang, Sun Dapeng, Jia Baixue, Huo Xiaochuan, Tong Xu, Wang Anxin, Ma Ning, Gao Feng, Mo Dapeng, Miao Zhongrong
Interventional Neuroradiology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, 100070, Fengtai District, Beijing, China.
Cerebrovascular Disease Department, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Clin Neuroradiol. 2024 Dec 20. doi: 10.1007/s00062-024-01484-2.
The Hyperdense Middle Cerebral Artery Sign (HMCAS) is an early marker of acute MCA occlusion on non-contrast CT (NCCT), which has been linked with stroke type and thrombus composition.
To assess the prognostic value of HMCAS in M1 occlusion patients treated with endovascular thrombectomy and explore its predictive value across different patients.
Patients with M1 occlusion were selected from the ANGEL-ACT registry, which comprised 1793 individuals. Cohorts were divided based on the presence of HMCAS. The primary outcome was functional independence (mRS 0-2) at 90 days. Secondary outcomes included excellent outcome (mRS 0-1), good functional outcome (mRS 0-3), modified first pass effect (mFPE), successful recanalization, intracranial hemorrhage, and 90-day mortality. Propensity score matching (PSM) was employed to adjust for confounders, with 96 patients in each matched group. Subgroup analysis was performed to determine whether the effect of HMCAS on clinical outcomes differed between groups.
Among 714 acute M1 occlusion patients, 96 (13.4%) had HMCAS. PSM analysis showed that HMCAS was independently associated with mFPE (OR: 1.97, 95% CI: 1.04-3.75, p = 0.038) but had no significant effects on other clinical outcomes. There was a significant association between HMCAS and functional independence for patients who underwent direct thrombectomy but not for patients who underwent bridging therapy (P for interaction = 0.033).
This study indicates that in patients with acute M1 occlusion undergoing EVT, HMCAS on pretreatment NCCT is not significantly associated with functional independence but is linked to a higher first-pass recanalization rate. Its clinical impact on outcomes depends on whether intravenous thrombolysis is administered before thrombectomy.
大脑中动脉高密度征(HMCAS)是非增强CT(NCCT)上急性大脑中动脉闭塞的早期标志物,与卒中类型和血栓成分有关。
评估HMCAS在接受血管内血栓切除术治疗的M1段闭塞患者中的预后价值,并探讨其在不同患者中的预测价值。
从包含1793例患者的ANGEL-ACT注册研究中选取M1段闭塞患者。根据是否存在HMCAS对队列进行分组。主要结局是90天时的功能独立(改良Rankin量表[mRS]评分0-2分)。次要结局包括良好结局(mRS评分0-1分)、良好功能结局(mRS评分0-3分)、改良首过效应(mFPE)、成功再通、颅内出血和90天死亡率。采用倾向评分匹配(PSM)来调整混杂因素,每个匹配组有96例患者。进行亚组分析以确定HMCAS对临床结局的影响在不同组之间是否存在差异。
在714例急性M1段闭塞患者中,96例(13.4%)有HMCAS。PSM分析显示,HMCAS与mFPE独立相关(比值比:1.97,95%置信区间:1.04-3.75,p = 0.038),但对其他临床结局无显著影响。对于接受直接血栓切除术的患者,HMCAS与功能独立之间存在显著关联,但对于接受桥接治疗的患者则无此关联(交互作用p = 0.033)。
本研究表明,在接受血管内治疗(EVT)的急性M1段闭塞患者中,治疗前NCCT上的HMCAS与功能独立无显著关联,但与较高的首过再通率相关。其对结局的临床影响取决于血栓切除术之前是否进行了静脉溶栓治疗。